ライフサイエンスコーパス: deferoxamine

1 iron chelators (deferiprone, deferasirox, or deferoxamine).

2 reduced promoter inducibility by hypoxia and deferoxamine.

3 ance chelation monotherapy with subcutaneous deferoxamine.

4 ubjects exposed to deferiprone compared with deferoxamine.

5 prove hepatic iron in thalassemia as well as deferoxamine.

6 ccurred in the presence of the iron chelator deferoxamine.

7 prone can unload myocardial iron faster than deferoxamine.

8 diomyocytes treatment with the iron chelator deferoxamine.

9 pared to a value of 11.5 for the siderophore deferoxamine.

10 nyl-p-phenylenediamine and the iron chelator deferoxamine.

11 ted with the iron chelators 2-2-dipyridyl or deferoxamine.

12 ct of SNP in HEK293 cells is also blocked by deferoxamine.

13 of the methacholine response associated with deferoxamine.

14 modulated during intravenous chelation with deferoxamine.

15 tration than the nonlipophilic iron chelator deferoxamine.

16 vely than the nonlipid soluble iron chelator deferoxamine.

17 the inhibitor of hydroxyl radical formation, deferoxamine.

18 chronic anemia patients who are treated with deferoxamine.

19 ceptor and by the endolysosome iron chelator deferoxamine.

20 cause by insufficient iron chelation, not by deferoxamine.

21 eatment with a prolyl hydroxylase inhibitor, deferoxamine.

22 e, and the equivalence of deferasirox versus deferoxamine.

23 ), which was alleviated by the iron chelator deferoxamine.

24 rent doses of deferasirox and the comparator deferoxamine.

25 Deferoxamine mesylate and starch-deferoxamine (1 mM) prevented bafilomycin-induced calcei

26 The iron chelator, deferoxamine (1 mM), and the endogenous.OH scavenger, as

27 hibition of S-nitrosocysteine decay, whereas deferoxamine (100 microM) was ineffective.

28 onds at 1 year (Gmeans ratio, 1.12) and with deferoxamine (11.6 milliseconds to 12.3 milliseconds; Gm

29 plus apamin, whereas endothelial denudation, deferoxamine, 1H-(1,2,4)-oxadiazole-[4,3-a]quinoxalin-1-

30 e presence of catalase, hypoxia (8% oxygen), deferoxamine, 3-aminobenzamide [an inhibitor of poly(ADP

31 s comparable between deferasirox (35.4%) and deferoxamine (30.8%).

32 arget dose 40 mg/kg per day) vs subcutaneous deferoxamine (50-60 mg/kg per day for 5-7 days/week) for

33 we examined the effects of the iron chelator deferoxamine (500 mg intra-arterially over 1 hour) on va

34 he antioxidants vitamin C (10 micromol/L) or deferoxamine (500 micromol/L) restored LV relaxant respo

35 igs were also treated with an iron chelator, deferoxamine, (50mg/kg, i.m.) or vehicle and killed at d

36 s, at which time either 67Ga-DF-folate, 67Ga-deferoxamine (67Ga-DF) or 67Ga-citrate was administered

37 (89)Zr-bevacizumab deferoxamine ((89)Zr-BVDFO) was prepared with a specific

38 lmost completely inhibited by treatment with deferoxamine, a cell-permeable iron chelator.

39 are powerful iron chelators comparable with deferoxamine, a clinically useful iron-chelating agent.

40 n this report, we investigate the ability of deferoxamine, a scavenger of free iron, the hydroxyl rad

41 Deferoxamine, a very high affinity chelator having log b

42 Administration of deferoxamine abrogated methylglyoxal conjugation, normal

43 Deferoxamine accounted for 71% of chelation-related char

44 d pigmentary retinopathy following high-dose deferoxamine administration.

45 emoval of iron was completely effected using deferoxamine, after which iron could be rebound to the l

46 nomycin D, and the G1/S cell cycle inhibitor deferoxamine, all promote survival after trophic factor

47 nsfusions, iron overload, noncompliance, and deferoxamine allergy.

48 enotypes by the cell-permeable iron chelator deferoxamine allowed the conclusion that increased level

49 ombined deferiprone with deferoxamine versus deferoxamine alone, and the equivalence of deferasirox v

50 Deferoxamine, alpha-tocopherol, and dimethylsulfoxide ea

51 Cobalt and deferoxamine also increased MKP-1 mRNA levels, suggestin

52 (89)Zr was complexed with deferoxamine (also known as desferrioxamine B, desferoxa

53 were treated with 5'-aminolevulenic acid and deferoxamine (an iron chelator) to accumulate porphyrins

54 nase C alpha and its suppression by EGCG and deferoxamine (an iron chelator), a possible mechanism in

55 lopurinol (a xanthine oxidase inhibitor), or deferoxamine (an iron chelator), suggesting that ROS may

56 r), Me2SO (a hydroxyl radical scavenger), or deferoxamine (an iron chelator).

57 4.7 macrophage cells treated with hypoxia or deferoxamine, an iron chelator mimicking hypoxia.

58 Deferoxamine, an iron chelator, and ferrostatin-1, a fer

59 tyl cysteine, a glutathione precursor, or by deferoxamine, an iron chelator.

60 animals were treated with either vehicle or deferoxamine, an iron chelator.

61 flow-induced vasodilatation was restored by deferoxamine, an iron chelator.

62 Deferoxamine, an iron sequestrating antioxidant, prevent

63 The antioxidants, deferoxamine and alpha-tocopherol, effectively prevented

64 lly, we show nitric oxide and iron chelators deferoxamine and deferiprone significantly inhibited pre

65 Hypoxic mimetics, such as deferoxamine and dimethyloxalylglycine, were also found

66 py was repressed, but were hypersensitive to deferoxamine and displayed a growth defect similar to th

67 The reducing agents deferoxamine and dithiothreitol reversed the ECA inhibit

68 The patient was on deferoxamine and had previous splenectomy surgery.

69 Two drug candidates, deferoxamine and imatinib, were identified from the high

70 Deferoxamine and iron may modulate CD47 expression.

71 l neurons is suppressed by the G1/S blockers deferoxamine and mimosine, as well as by the CDK-inhibit

72 Trastuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr.

73 Pertuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr.

74 ease in susceptibility to the iron-chelators deferoxamine and salicylhydroxamic acid.

75 Methods: Bevacizumab was conjugated with deferoxamine and subsequently radiolabeled with (89)Zr.

76 ic protoporphyria) or with the iron chelator deferoxamine and the porphyrin precursor 5-aminolevulini

77 H(2)O(2) were prevented by the iron chelator deferoxamine and the vitamin E analog Trolox, suggesting

78 r currently used is deferasirox, followed by deferoxamine and then combination therapies.

79 the trial with continuation of subcutaneous deferoxamine and were randomized to receive additional o

80 se, dimethyl thiourea, superoxide dismutase, deferoxamine, and dimethyl sulfoxide significantly inhib

81 The reducing agents, dithionite, deferoxamine, and dithiothreitol, reversed and exogenous

82 tramethylchroman-2-carboxylic acid (Trolox), deferoxamine, and U-74389G.

83 Deferoxamine appears capable of binding to gadolinium io

84 lowed by 8 mg/kg/hr for 90 mins or 100 mg/kg deferoxamine at -15 mins or vehicle.

85 the G1/S blockers mimosine, ciclopirox, and deferoxamine at concentrations that correlate with their

86 nterrupted infusion of high-dose intravenous deferoxamine, augmented by oral deferiprone.

87 Citrate (Cit) and Deferoxamine B (DFOB) are two important organic ligands

88 ynthesis, namely, 4,6-dioxoheptanoic acid or deferoxamine; (b) This increased stability of 5-aminolev

89 ent with antioxidants (ascorbate, Trolox, or deferoxamine), but was prevented by the NMDA receptor an

90 n be blocked by the peroxynitrite scavenger, deferoxamine, but not by dithiothreitol, which triggers

91 ke of Fe was stimulated two- to threefold by deferoxamine, but this increment could be abolished by c

92 The (89)Zr-p-isothiocyanatobenzyl-deferoxamine-CD3 PET probe was assessed in a murine tumo

93 Among 330 patients who had received deferoxamine chelation therapy, 224 (68%) reported no co

94 per patient decade for patients who require deferoxamine chelation.

95 at pharmacological activators of HIF-1 (e.g. deferoxamine, cobalt chloride) could also protect cultur

96 son to the standard chelation monotherapy of deferoxamine, combination treatment with additional defe

97 in C and by -8.9+/-2.2 ms in the presence of deferoxamine compared with -0.8+/-2.2 ms in the absence

98 Methods: Deferoxamine conjugation and (89)Zr radiolabeling were o

99 chelatable iron, 16%, p < 0.01 (59Fe in the deferoxamine-containing medium), and decreased 59Fe in f

100 -1alpha-stabilizing drugs: the iron chelator deferoxamine (Desferal [DFO]), a neddylation inhibitor (

101 )I via an iodination reagent or coupled with deferoxamine (Df) and complexed with (89)Zr.

102 aluate the whole-body distribution of (89)Zr-deferoxamine (Df)-pembrolizumab in two rodent models (mi

103 ophene) (PEDOT) into which an iron chelator, deferoxamine (DFA), has been doped during the polymeriza

104 Both deferoxamine (DFO) and ethylenediaminetetraacetic acid (

105 g studies, alpha-hTSPAN8 was conjugated with deferoxamine (DFO) and radiolabeled with (89)Zr, a posit

106 The iron chelator deferoxamine (DFO) has been shown to improve skin vascul

107 Deferoxamine (DFO) has shown therapeutic promise for the

108 ive phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patients with severe transfusional

109 (Fc) and iron chelating moieties composed of deferoxamine (DFO) into the final gel scaffold in revers

110 Deferoxamine (DFO) is a high-affinity Fe (III) chelator

111 Methods: Bifunctional deferoxamine (DFO) isothiocyanate was used to synthesize

112 Experimental studies suggest that deferoxamine (DFO) limits the generation of reactive oxy

113 parative purposes, we have also administered deferoxamine (DFO) PO and sc in aqueous solution at a do

114 Deferoxamine (DFO) represents a widely used iron chelato

115 c bioconjugation methods were used to append deferoxamine (DFO) to a trio of monoclonal antibodies: t

116 on by giving equimolar amounts of NaHBED and deferoxamine (DFO) to Cebus apella monkeys as either a s

117 ddition, administration of the iron chelator deferoxamine (DFO) to mice prior to administration of to

118 ampal neuron cultures with the iron chelator deferoxamine (DFO) to model chronic energetic insufficie

119 alfa was synthesized by conjugating p-SCN-Bn-deferoxamine (DFO) to thyrotropin-alfa in a molar ratio

120 Retentates treated with the chelator deferoxamine (DFO) yielded a peak that comigrated with t

121 Deferoxamine (DFO), an antioxidant and iron chelator kno

122 ) containing the FDA-approved small molecule deferoxamine (DFO), an iron chelator that increases HIF-

123 Deferoxamine (DFO), an iron-chelating agent clinically u

124 s developed to measure simultaneously NTBPI, deferoxamine (DFO), and its major metabolite.

125 he current gold standard chelators, DOTA and deferoxamine (DFO), conjugated to IAB2MA for radiolabeli

126 arize the properties of each of the 3 drugs, deferoxamine (DFO), deferiprone (DFP), and deferasirox (

127 e zirconium 89 ((89)Zr) through the chelator deferoxamine (DFO), or (89)Zr-DFO-daratumumab, for immun

128 solution, PS conjugated to the iron chelator deferoxamine (DFO), or lactated Ringer's solution alone

129 d by subcutaneous (SC) injection of HBED and deferoxamine (DFO), the reference chelator, in rodents a

130 ad PET/CT comparison of (124)I versus (89)Zr-deferoxamine (DFO)-F(ab')(2) antigal-3 was performed, fo

131 stribution and PET imaging of the [(89)Zr]Zr-deferoxamine (DFO)-N4MU01 radioimmunoconjugate was studi

132 -acetyl-L-cysteine, or by the iron scavenger deferoxamine (DFO).

133 uced following addition of the iron chelator deferoxamine (DFO).

134 e complex structure of the widely used drug, deferoxamine (DFO).

135 0% injected dose in 4 h), compared to native deferoxamine (DFO).

136 x (DFX; Exjade, Novartis) is not inferior to deferoxamine (DFO; Desferal, Novartis) for the removal o

137 DLL3 antibody SC16.56 conjugated to p-SCN-Bn-deferoxamine [DFO] serving as a chelator for zirconium-8

138 This study examined the role of deferoxamine (DFX) in brain injury and HT in a rat model

139 hus, the iron chelators deferiprone (L1) and deferoxamine (Dfx), which are already used to treat iron

140 but 3 mg/kg Desmethyl tirilazad or 100 mg/kg deferoxamine does not.

141 and iron availability through treatment with deferoxamine dramatically increased Zygomycetes pathogen

142 ite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent

143 The ability of a 67Ga-labeled deferoxamine-folate conjugate (67Ga-DF-folate) to target

144 noninferiority of deferasirox compared with deferoxamine for myocardial iron removal.

145 e combined treatment group compared with the deferoxamine group in myocardial T2* (ratio of change in

146 ndomized to receive additional oral placebo (deferoxamine group) or oral deferiprone 75 mg/kg per day

147 In normal volunteers, deferoxamine had no effect on the response to methacholi

148 t iron/hydrogen peroxide-induced DNA damage; deferoxamine had no effect.

149 Although this alternative to parenteral deferoxamine has been a major advance for patients with

150 For three decades, deferoxamine has been the only approved iron chelator.

151 s maintained on the parenteral iron chelator deferoxamine have myocardial iron loading.

152 diet supplement or with hydroxyethyl starch deferoxamine (HES-DFO) by weekly intravenous injections

153 Deferoxamine improved nitric oxide-mediated, endothelium

154 Deferoxamine improved the blood flow response to methach

155 Neither desmethyl tirilazad nor deferoxamine improves pathologic results.

156 These results indicate that deferoxamine improves spatial memory performance, possib

157 Furthermore, the protective effect of deferoxamine in cisplatin-induced AKI was apparent in he

158 as observed with infected cells treated with deferoxamine in comparison to growth under iron-replete

159 ption of the cSHMT gene is also inhibited by deferoxamine in MCF-7 cells, indicating that mimosine in

160 type was to treatment with the Fe3+ chelator deferoxamine, indicating that it is defective for intrac

161 pounds were found to inhibit hypoxia but not deferoxamine-induced HIF-1alpha protein stabilization.

162 Subjects were admitted for 4 assessments: deferoxamine infusion and urinary iron measurement to as

163 Deferoxamine infusion decreased serum iron levels (P<0.0

164 ional iron overload have depended on nightly deferoxamine infusions for iron chelation.

165 strated that the iron chelators mimosine and deferoxamine inhibit DNA replication in mammalian cells,

166 Desmethyl tirilazad (20 mg/kg) and 100 mg/kg deferoxamine inhibit lipid peroxidation.

167 The antioxidants tempol, ebselen, and deferoxamine inhibited CO-induced O2*- production and co

168 for cancer cells and demonstrate repurposing deferoxamine into an effective anticancer drug via mitoc

169 Tests used Mb-knockout or treatment with deferoxamine iron chelator (DFO).

170 ration in chronic anemia patients treated by deferoxamine is cause by insufficient iron chelation, no

171 iently treated iron overloading and not only deferoxamine is the cause of the retinal degeneration.

172 t has been proposed that in combination with deferoxamine it may have additional effect.

173 oxidation (ferrostatin-1) or chelating iron (deferoxamine) largely suppresses iron accumulation-induc

174 Other siderophores (pyoverdine, ferrichrome, deferoxamine) likewise inhibited ROS and NETs in neutrop

175 at the time of enrolment, and were receiving deferoxamine (<100 mg/kg per day) or deferasirox (<40 mg

176 ation of the bacteria with the iron chelator deferoxamine markedly inhibited the magnitude of .OH spi

177 hage were randomly assigned (1:1) to receive deferoxamine mesylate (32 mg/kg per day) or placebo (sal

178 ing the intracellular iron-chelating reagent deferoxamine mesylate (Desferal).

179 Both hypoxia-mimetic deferoxamine mesylate (DFO) and TGF-beta1 inhibited adip

180 compared to those of three metal chelators; deferoxamine mesylate (DFO), 1,10-phenanthroline (o-phen

181 e to increase the nose-to-brain transport of deferoxamine mesylate (DFO), a neuroprotector unable to

182 generation, we studied if an iron chelator, deferoxamine mesylate (DFO), alone or in combination wit

183 The use of deferoxamine mesylate (DFO), an iron chelator, to treat

184 bital infusion of PP-IX or the iron chelator deferoxamine mesylate (DFO), with the first committed he

185 the PAN reagent, the Fe(III) masking agents deferoxamine mesylate (DFO-B) or disodium 4,5-dihydroxy-

186 Ten (7%) participants in the deferoxamine mesylate and 11 (7%) in the placebo group d

187 p53 in response to hypoxia mimetics such as deferoxamine mesylate and CoCl(2), regardless of their H

188 hat the structurally distinct iron chelators deferoxamine mesylate and mimosine prevent apoptosis ind

189 Deferoxamine mesylate and starch-deferoxamine (1 mM) pre

190 on consisted of 144 patients assigned to the deferoxamine mesylate group and 147 assigned to the plac

191 outcome, 48 (34%) of 140 participants in the deferoxamine mesylate group, and 47 (33%) of 143 patient

192 reported in 39 (27%) of 144 patients in the deferoxamine mesylate group, and 78 serious adverse even

193 bined exposure to 1A10 and the iron chelator deferoxamine mesylate has synergistic antiproliferative

194 Moreover, upmodulation by deferoxamine mesylate implicates huntingtin as an iron-r

195 ed to assess the safety of the iron chelator deferoxamine mesylate in patients with intracerebral hae

196 n or the membrane-impermeable iron chelator, deferoxamine mesylate salt, was able to increase MT2 lev

197 8-fold more susceptible to the iron chelator deferoxamine mesylate than hRRM2, although the iron cont

198 showed that further study of the efficacy of deferoxamine mesylate with anticipation that the drug wo

199 increased to 7.4, antioxidants (allopurinol, deferoxamine mesylate, and glutathione), vasodilators (a

200 lyzing a commercially available siderophore, deferoxamine mesylate, in both the free ligand and Fe-bo

201 nical outcome was less than 12% in favour of deferoxamine mesylate, then to move to a phase 3 efficac

202 tional activity of stabilized p53 induced by deferoxamine mesylate, which mimics hypoxia, in normal c

203 1 activity and HIF-1alpha protein induced by deferoxamine mesylate.

204 duced by treatment with the hypoxia mimetic, deferoxamine mesylate.

205 ; and (3) G1 blockers, such as rapamycin and deferoxamine, mimicked the anti-proliferative effects of

206 describe the use of mitochondrially targeted deferoxamine (mitoDFO) as a novel approach to preferenti

207 with antioxidants (dithiothreitol, trolox or deferoxamine, nitric oxide synthase inhibitor (N(G)-mono

208 superoxide dismutase (O(2)(.) scavenger) or deferoxamine (OH. inhibitor).

209 ndosteal endothelium with the small molecule deferoxamine or a genetic approach rescues HSCs loss, pr

210 tivity was pharmacologically inhibited using deferoxamine or dimethyloxaloylglycine, and also when th

211 ts from astrocytoma cells exposed to iron or deferoxamine over different time intervals.

212 stablishing noninferiority of deferasirox vs deferoxamine (P = .057 for superiority of deferasirox).

213 nt of mucin with iron chelator DIBI, but not deferoxamine, partially abolished its virulence enhancem

214 s reported, in which a high dose of p-SCN-Bn-deferoxamine-porphyrin-PEG nanocomplex (Df-PPN) is first

215 Deferoxamine pretreatment also diminishes gadd153 induct

216 Chelation of the iron with deferoxamine prevented this process as did melatonin whi

217 neal epithelial cells with the iron chelator deferoxamine prevents the appearance of nuclear ferritin

218 In diabetic mice, deferoxamine promoted neovascularization and enhanced wo

219 s with the iron chelators phenanthroline and deferoxamine protected them from candidal injury, even t

220 In addition, systemic treatment of deferoxamine reduced ICH-induced LCN2 upregulation (p<0.

221 Deferoxamine reduces free radicals by chelating iron and

222 elated retinal hemorrhagic lesions in utero, deferoxamine-related decreases in vision, ocular allergy

223 Mitochondrial targeting of deferoxamine represents a way to deprive cancer cells of

224 The iron chelator deferoxamine rescued FRDA fibroblasts more than controls

225 or catalase, or the chelation of nickel with deferoxamine, resulted in inhibition of NFAT activation.

226 inhibitor) or the chelation of vanadate with deferoxamine, resulted in inhibition of NFAT activation.

227 inhibitor), or the chelation of vanadate by deferoxamine, resulted in inhibition of p53 activation a

228 Deferoxamine retinopathy is the informally designated te

229 Deferoxamine retinopathy primarily targets the RPE-Bruch

230 Unconjugated 67Ga-deferoxamine showed no tumor affinity.

231 markedly by the HIF-1 activators hypoxia or deferoxamine, suggesting that it could operate in a nega

232 hows superior efficacy of deferiprone versus deferoxamine, the superiority of combined deferiprone wi

233 ctions in LIC after 1 year of deferasirox or deferoxamine therapy correlated with transfusional iron

234 Patients who underwent deferoxamine therapy had a significant reduction of GLC

235 y from the values at the time of change from deferoxamine to deferiprone in either the intention-to-t

236 ndings show that targeting the iron chelator deferoxamine to mitochondria impairs mitochondrial respi

237 everal oral iron chelators and variations of deferoxamine to prolong the half-life have been develope

238 eased vision following high-dose intravenous deferoxamine to treat systemic iron overload.

239 on of antioxidants 2-methyl aminochroman and deferoxamine to UW solution inhibited necrotic cell deat

240 However, deferoxamine-treated animals showed significant improvem

241 aining electron-dense particles, whereas ALA+deferoxamine treatment resulted in higher PP-IX in the c

242 eral white and gray matter in pigs which had deferoxamine treatment.

243 ntel) and antioxidant (N-acetylcysteine plus deferoxamine) treatments was effective in inhibiting mos

244 the superiority of combined deferiprone with deferoxamine versus deferoxamine alone, and the equivale

245 ed for use in children aged <2 years so only deferoxamine was being used in these patients).

246 induction of NDRG1 expression by hypoxia and deferoxamine was diminished by RNA interference knockdow

247 ement conferring inducibility by hypoxia and deferoxamine was localized to an early growth response 1

248 Deferoxamine was used to inhibit depolymerization during

249 h as diethylenetriamine pentaacetic acid and deferoxamine, we reveal that a unique histidine at posit

250 ssion as well as iron-chelating treatment by Deferoxamine were able to restore the LD amount and RR.

251 hanolamine with encapsulated glutathione and deferoxamine, were prepared and labeled with 99mTc and 1

252 Deferoxamine, which chelates iron, interacts with free h

253 ffect can be reversed with the iron chelator deferoxamine, which results in hypoxia-inducible factor

254 ing studies was assessed by injecting (89)Zr-deferoxamine-Z(EGFR:03115) (2.4-3.6 MBq, 2 mug) either t

255 g 10 mug of nonlabeled molecules with (89)Zr-deferoxamine-Z(EGFR:03115) allows for clear tumor visual